Amgen and Genentech are the two biggest Bio tech Industries who have great dominant in the Share Market.
This rapid growth in the U.S. Bio market will be mainly driven by biogeneric TNF-alpha inhibitors for rheumatoid arthritis, which will generate $700 million in sales by 2016, and there is a strong backup by biogeneric versions of interferon-betas for multiple sclerosis,
Moreover, Herceptin for breast cancer, and ESPs for chemotherapy-induced anemia, each of which will post more than $250 million in 2016 U.S. sales.
Further, the launch of biogeneric TNF-alpha inhibitors in 2012, the U.S. biogeneric market will expand substantially through 2016 and reach a total of $2 billion in annual sales.
These are the 10 biotech companies which have a good market shares for the past years and one have to look upon the pipelines before feeding their work on it.
1. Amgen
2. Roche/Genentech
3. Johnson & Johnson
4. Novo Nordisk
5. Eli Lilly
6. Sanofi-Aventis
7. Abbott
8. Merck KGaA
9. Schering-Plough
10. Wyeth
In the face of generic competition and other market pressures, companies are looking for strategies to ensure their futures. They put their maximum effort to ensure that they are stable in the market. Biologics offer an opportunity for growth that can't be ignored.
